183 related articles for article (PubMed ID: 20118205)
1. Characterization of pulmonary arterial hypertension patients walking more than 450 m in 6 min at diagnosis.
Degano B; Sitbon O; Savale L; Garcia G; O'Callaghan DS; Jaïs X; Humbert M; Simonneau G
Chest; 2010 Jun; 137(6):1297-303. PubMed ID: 20118205
[TBL] [Abstract][Full Text] [Related]
2. Submaximal exercise testing may be superior to the 6-min walk test in assessing pulmonary arterial hypertension disease severity.
Neal JE; Lee AS; Burger CD
Clin Respir J; 2014 Oct; 8(4):404-9. PubMed ID: 24308300
[TBL] [Abstract][Full Text] [Related]
3. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials.
Savarese G; Paolillo S; Costanzo P; D'Amore C; Cecere M; Losco T; Musella F; Gargiulo P; Marciano C; Perrone-Filardi P
J Am Coll Cardiol; 2012 Sep; 60(13):1192-201. PubMed ID: 22995024
[TBL] [Abstract][Full Text] [Related]
4. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
[TBL] [Abstract][Full Text] [Related]
5. Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry.
Barst RJ; Chung L; Zamanian RT; Turner M; McGoon MD
Chest; 2013 Jul; 144(1):160-168. PubMed ID: 23429998
[TBL] [Abstract][Full Text] [Related]
6. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study.
Huo Y; Jing ZC; Zeng XF; Liu JM; Yu ZX; Zhang GC; Li Y; Wang Y; Ji QS; Zhu P; Wu BX; Zheng Y; Wang PP; Li J
BMC Cardiovasc Disord; 2016 Oct; 16(1):201. PubMed ID: 27770771
[TBL] [Abstract][Full Text] [Related]
8. A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension.
Sanges S; Launay D; Rhee RL; Sitbon O; Hachulla É; Mouthon L; Guillevin L; Rottat L; Montani D; De Groote P; Cottin V; Magro P; Prévot G; Bauer F; Bergot E; Chabanne C; Reynaud-Gaubert M; Leroy S; Canuet M; Sanchez O; Gut-Gobert C; Dauphin C; Pison C; Boissin C; Habib G; Clerson P; Conesa F; Cordier JF; Kawut SM; Simonneau G; Humbert M
Ann Rheum Dis; 2016 Aug; 75(8):1457-65. PubMed ID: 26324844
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials.
Benza RL; Gomberg-Maitland M; Naeije R; Arneson CP; Lang IM
J Heart Lung Transplant; 2011 Sep; 30(9):982-9. PubMed ID: 21531577
[TBL] [Abstract][Full Text] [Related]
10. Impact of pulmonary hemodynamics on 6-min walk test in idiopathic pulmonary fibrosis.
Minai OA; Santacruz JF; Alster JM; Budev MM; McCarthy K
Respir Med; 2012 Nov; 106(11):1613-21. PubMed ID: 22902266
[TBL] [Abstract][Full Text] [Related]
11. Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study.
Langleben D; Galiè N; He J; Huang Y; Humbert M; Keogh A; Rubin LJ; Zhou D; Curram J; Davie N; Ghofrani HA
J Heart Lung Transplant; 2015 Mar; 34(3):338-47. PubMed ID: 25703961
[TBL] [Abstract][Full Text] [Related]
12. Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1.
Frantz RP; McDevitt S; Walker S
J Heart Lung Transplant; 2012 Aug; 31(8):811-6. PubMed ID: 22759797
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost.
Han X; Zhang Y; Dong L; Fang L; Chai Y; Niu M; Yu Y; Liu L; Yang X; Qu S; Li S
Respir Care; 2017 Apr; 62(4):489-496. PubMed ID: 28119496
[TBL] [Abstract][Full Text] [Related]
14. Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in 6 minute walk distance and quality of life.
Strange G; Keogh AM; Williams TJ; Wlodarczyk J; McNeil KD; Gabbay E
Respirology; 2008 Sep; 13(5):674-82. PubMed ID: 18713089
[TBL] [Abstract][Full Text] [Related]
15. Outcome of pulmonary hypertension subjects transitioned from intravenous prostacyclin to oral bosentan.
Safdar Z
Respir Med; 2009 Nov; 103(11):1688-92. PubMed ID: 19539456
[TBL] [Abstract][Full Text] [Related]
16. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.
Sitbon O; Beghetti M; Petit J; Iserin L; Humbert M; Gressin V; Simonneau G
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():25-31. PubMed ID: 16919007
[TBL] [Abstract][Full Text] [Related]
17. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary Hypertension in Patients With COPD: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).
Vizza CD; Hoeper MM; Huscher D; Pittrow D; Benjamin N; Olsson KM; Ghofrani HA; Held M; Klose H; Lange T; Rosenkranz S; Dumitrescu D; Badagliacca R; Claussen M; Halank M; Vonk-Noordegraaf A; Skowasch D; Ewert R; Gibbs JSR; Delcroix M; Skride A; Coghlan G; Ulrich S; Opitz C; Kaemmerer H; Distler O; Grünig E
Chest; 2021 Aug; 160(2):678-689. PubMed ID: 33581097
[TBL] [Abstract][Full Text] [Related]
19. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension.
Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost A; Engel P; Kramer MR; Serdarevic-Pehar M; Layton GR; Sitbon O; Badesch DB;
J Heart Lung Transplant; 2014 Jul; 33(7):689-97. PubMed ID: 24815795
[TBL] [Abstract][Full Text] [Related]
20. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.
Barst RJ; Langleben D; Badesch D; Frost A; Lawrence EC; Shapiro S; Naeije R; Galie N;
J Am Coll Cardiol; 2006 May; 47(10):2049-56. PubMed ID: 16697324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
